Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.

Ueno M, Su YY, Takai A, Huang YH, Morimura H, Nishijima N, Lin SM, Chang CW, Iwamoto S, Nagatomo S, Lai HC, Mitani T, Ikeda A, Uenoyama Y, Umeda M, Chen SC, Chuang CH, Lai SW, Lee TY, Nakano S, Dai CY, Goto T, Su TH, Hsu CS, Lo CC, Takeda H, Osaki Y, Hatano E, Lee PC, Lin PT, Wang HW, Hsu WF, Liu TH, Seno H

Open source

DOI: 10.1159/000552808
Published: 2026 Jun 1
Container: Liver cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1159/000552808,
  title = {Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.},
  author = {Ueno M and Su YY and Takai A and Huang YH and Morimura H and Nishijima N and Lin SM and Chang CW and Iwamoto S and Nagatomo S and Lai HC and Mitani T and Ikeda A and Uenoyama Y and Umeda M and Chen SC and Chuang CH and Lai SW and Lee TY and Nakano S and Dai CY and Goto T and Su TH and Hsu CS and Lo CC and Takeda H and Osaki Y and Hatano E and Lee PC and Lin PT and Wang HW and Hsu WF and Liu TH and Seno H},
  year = {2026},
  journal = {Liver cancer},
  doi = {10.1159/000552808},
  url = {https://doi.org/10.1159/000552808}
}

RIS

TY  - JOUR
TI  - Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.
AU  - Ueno M
AU  - Su YY
AU  - Takai A
AU  - Huang YH
AU  - Morimura H
AU  - Nishijima N
AU  - Lin SM
AU  - Chang CW
AU  - Iwamoto S
AU  - Nagatomo S
AU  - Lai HC
AU  - Mitani T
AU  - Ikeda A
AU  - Uenoyama Y
AU  - Umeda M
AU  - Chen SC
AU  - Chuang CH
AU  - Lai SW
AU  - Lee TY
AU  - Nakano S
AU  - Dai CY
AU  - Goto T
AU  - Su TH
AU  - Hsu CS
AU  - Lo CC
AU  - Takeda H
AU  - Osaki Y
AU  - Hatano E
AU  - Lee PC
AU  - Lin PT
AU  - Wang HW
AU  - Hsu WF
AU  - Liu TH
AU  - Seno H
PY  - 2026
JO  - Liver cancer
DO  - 10.1159/000552808
UR  - https://doi.org/10.1159/000552808
ER  -

APA

M, U., YY, S., A, T., YH, H., H, M., N, N., SM, L., CW, C., S, I., S, N., HC, L., T, M., A, I., Y, U., M, U., SC, C., CH, C., SW, L., TY, L., S, N., CY, D., T, G., TH, S., CS, H., CC, L., H, T., Y, O., E, H., PC, L., PT, L., HW, W., WF, H., TH, L., & H, S. (2026). Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.. Liver cancer. https://doi.org/10.1159/000552808

Source records

pubmed · retrieved 2026-09-26T10:28:46.002Z